Cargando…

Arming the oncolytic virus enadenotucirev (EnAd) to generate enhanced locally-acting immunotherapies for cancer

Detalles Bibliográficos
Autores principales:	Champion, Brian R, Rasiah, Nalini, Illingworth, Sam, Calderon, Hugo, Besneux, Matthieu, Lear, Rochelle, Plumb, Darren, Kodialbail, Prithvi, Brown, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649419/ http://dx.doi.org/10.1186/2051-1426-3-S2-P334

Ejemplares similares

"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
por: Champion, Brian R, et al.
Publicado: (2014)

Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes
por: Marino, Nalini, et al.
Publicado: (2017)

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
por: Illingworth, Sam, et al.
Publicado: (2017)

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
por: Dyer, Arthur, et al.
Publicado: (2016)

Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation
por: Taverner, William K., et al.
Publicado: (2019)

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
por: Machiels, Jean-Pascal, et al.
Publicado: (2019)

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase
por: Pokrovska, Tzveta D., et al.
Publicado: (2020)

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
por: Garcia-Carbonero, Rocio, et al.
Publicado: (2017)

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
por: O’Cathail, Séan M., et al.
Publicado: (2020)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Cowpox Virus: A New and Armed Oncolytic Poxvirus
por: Ricordel, Marine, et al.
Publicado: (2017)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
por: Fakih, Marwan, et al.
Publicado: (2023)

Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment
por: Gryciuk, Aleksander, et al.
Publicado: (2023)

Armed oncolytic viruses: A kick-start for anti-tumor immunity
por: de Graaf, J.F., et al.
Publicado: (2018)

Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer
por: Ang, Lin, et al.
Publicado: (2022)

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy
por: Xia, Mao, et al.
Publicado: (2019)

Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo
por: Zhu, Wei, et al.
Publicado: (2012)

Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus
por: Yang, Yu, et al.
Publicado: (2015)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses
por: Farrera-Sal, Martí, et al.
Publicado: (2020)

Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules
por: Peters, Cole W. D., et al.
Publicado: (2021)

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus
por: Wan, Peter Kok-Ting, et al.
Publicado: (2021)

TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer
por: Ziauddin, Mohammed F, et al.
Publicado: (2010)

Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models
por: Zhang, Kai-Liang, et al.
Publicado: (2019)

Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness
por: Farrera-Sal, Martí, et al.
Publicado: (2020)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
por: Guo, Zong Sheng, et al.
Publicado: (2020)

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12
por: Fukuhara, Hiroshi, et al.
Publicado: (2023)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
por: Rodríguez, María Del Carmen Rodríguez, et al.
Publicado: (2022)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models
por: Man, Yang Kee Stella, et al.
Publicado: (2022)

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2015)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses
por: Sampath, Padma, et al.
Publicado: (2013)

An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy
por: Deng, Lili, et al.
Publicado: (2020)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus
por: He, Xu, et al.
Publicado: (2023)

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity
por: Xie, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_trf1ov315egaqc91tig3n78n4t